Clinical Trial Detail

NCT ID NCT01998971
Title A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

multiple myeloma

Therapies

Pomalidomide

Bortezomib + Dexamethasone

Melphalan

Thalidomide

Lenalidomide

Prednisone

Daratumumab

Carfilzomib

Diphenhydramine

Montelukast

Age Groups: adult

No variant requirements are available.